UK govt offers "step change" in support of regenerative medicine
This article was originally published in Clinica
Executive Summary
The UK is at the forefront of regenerative medicine (RM) and has "huge potential" to produce commercially viable therapies and other technologies for a range of diseases. However, for this to happen, the right kind of regulatory and financial support must be provided, a range of scientific and other issues must be overcome, and companies must choose carefully what kind of products or technologies they are prepared to invest in.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.